Incyte to Pay Novartis $280M in Settlement Over Jakafi Royalty Dispute
核心洞察
Incyte and Novartis have reached a settlement agreement over a long-running dispute regarding royalty payments for the blood cancer (搜索) treatment Jakafi, with Incyte agreeing to pay Novartis $280 million.
The dispute stemmed from a 2009 collaboration agreement that allowed Novartis to develop and commercialize Jakafi outside the U.S., with Incyte allegedly reducing payments by 50% in 2019 and planning to stop royalties entirely after 2021.
Jakafi generated $2.7 billion in sales for Incyte in the previous year, plus $418 million in royalty revenues, while Novartis recorded $1.9 billion in sales from the JAK inhibitor (搜索).
Incyte Corporation and Novartis AG have reached a settlement agreement to resolve their years-long dispute over royalty payments related to the blockbuster blood cancer (搜索) treatment Jakafi (ruxolitinib), according to recent court filings. Incyte has agreed to pay Novartis $280 million as part of the settlement, effectively ending the legal battle just days before their scheduled May 5 trial date.
The dispute centered around a 2009 collaboration agreement that granted Novartis rights to develop and commercialize the JAK inhibitor (搜索) outside the United States. Under the terms of that agreement, both companies were obligated to pay each other royalties based on Jakafi sales in their respective territories, with Novartis offering up to $1.1 billion in potential milestone payments to Incyte.
Origins of the Dispute
The conflict began in May 2019 when, according to Novartis's 2020 lawsuit, Incyte "unilaterally" reduced its royalty payments to Novartis by 50%. The Swiss pharmaceutical giant further alleged that Incyte planned to cease royalty payments entirely after 2021. At the time of filing the complaint, Novartis claimed Incyte owed approximately $27.5 million plus interest in missed royalty payments.
In its legal complaint, Novartis asserted that Incyte had "taken advantage of its relationship" with Novartis to transform from a company with approximately $9 million in annual revenue to the billion-dollar pharmaceutical company it is today. Novartis further alleged that with this commercial success, Incyte attempted to "rewrite the parties' bargain."
Commercial Impact and Market Performance
Jakafi has proven to be a significant revenue generator for both companies. In the previous fiscal year, Incyte reported $2.7 billion in Jakafi sales, plus an additional $418 million in royalty revenues. Novartis, marketing the drug outside the U.S., recorded $1.9 billion in annual sales.
The JAK inhibitor (搜索) is approved for several indications including myelofibrosis (搜索), polycythemia vera (搜索), and steroid-refractory acute graft-versus-host disease (搜索). Its commercial success has been a major driver of Incyte's growth over the past decade.
Settlement Details
District Judge Gregory H. Woods has adjourned the planned trial following the joint request from both companies in favor of finalizing the settlement agreement. The $280 million payment from Incyte to Novartis appears to resolve all outstanding claims related to the royalty dispute.
It's worth noting that Incyte now markets a topical formulation of ruxolitinib under the brand name Opzelura, which is not included in the license agreement with Novartis, according to Incyte's earnings reports.
Industry Implications
This settlement highlights the complex nature of pharmaceutical collaborations and the potential for disagreements over revenue-sharing arrangements as products achieve commercial success. For investors and industry observers, the resolution provides clarity on Incyte's financial obligations and removes a significant legal uncertainty that had been hanging over both companies.
The agreement comes at a time when both companies are focusing on expanding their portfolios beyond their established products. For Incyte, resolving this dispute allows management to direct more attention toward advancing its pipeline and growing newer commercial products without the distraction of ongoing litigation with a major partner.